Alkermes plc [ALKS] stock prices are up 0.26% to $30.75 at the moment. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The ALKS shares have gain 0.49% over the last week, with a monthly amount glided 9.08%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Alkermes plc [NASDAQ: ALKS] stock has seen the most recent analyst activity on November 05, 2024, when Stifel upgraded its rating to a Buy and also boosted its price target to $36 from $25. Previously, TD Cowen started tracking the stock with Buy rating on June 17, 2024, and set its price target to $34. On March 19, 2024, Robert W. Baird initiated with a Outperform rating and assigned a price target of $37 on the stock. UBS downgraded its rating to a Sell but stick to its price target of $25 on February 20, 2024. Evercore ISI upgraded its rating to Outperform for this stock on October 24, 2023. In a note dated October 17, 2023, UBS initiated an Neutral rating and provided a target price of $31 on this stock.
The stock price of Alkermes plc [ALKS] has been fluctuating between $22.90 and $32.88 over the past year. Currently, Wall Street analysts expect the stock to reach $37.5 within the next 12 months. Alkermes plc [NASDAQ: ALKS] shares were valued at $30.75 at the most recent close of the market. An investor can expect a potential return of 21.95% based on the average ALKS price forecast.
Analyzing the ALKS fundamentals
The Alkermes plc [NASDAQ:ALKS] reported sales of 1.51B for trailing twelve months, representing a drop of -0.73%. Gross Profit Margin for this corporation currently stands at 0.82% with Operating Profit Margin at 0.21%, Pretax Profit Margin comes in at 0.22%, and Net Profit Margin reading is 0.22%. To continue investigating profitability, this company’s Return on Assets is posted at 0.15, Equity is 0.26 and Total Capital is 0.18. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.22.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 30.29 points at the first support level, and at 29.84 for the second support level. However, for the 1st resistance point, the stock is sitting at 31.19, and for the 2nd resistance point, it is at 31.64.
Ratios To Look Out For
It’s worth pointing out that Alkermes plc [NASDAQ:ALKS]’s Current Ratio is 3.45. In addition, the Quick Ratio stands at 3.03 and the Cash Ratio stands at 0.87. Considering the valuation of this stock, the price to sales ratio is 3.31, the price to book ratio is 3.85 and price to earnings (TTM) ratio is 15.66.
Transactions by insiders
Recent insider trading involved Hopkinson Craig C., EVP R&D, Chief Medical Officer, that happened on Dec 09 ’24 when 61151.0 shares were sold. Director, LAURENCIN CATO T completed a deal on Dec 09 ’24 to sell 2691.0 shares. Meanwhile, Director LAURENCIN CATO T bought 2691.0 shares on Dec 09 ’24.
